LAG-3/PD-1 Inhibitor Therapy in Unresectable or Metastatic Melanoma: The RELATIVITY-047 Trial
November 29th 2022Sajeve Thomas, MD, reflects on the RELATIVITY-047 trial combining relatlimab, a LAG-3 inhibitor, with nivolumab, a PD-1 inhibitor, in the first-line setting of unresectable or metastatic melanoma.
Watch
Episode 11A: Effect of Trilaciclib in Patients Receiving Chemotherapy for ES-SCLC Treatment
November 29th 2022Dr Paul Bunn briefly reviews key efficacy data from a pooled analyses of trilaciclib in chemotherapy induced myelosuppression and discusses strategies to manage neutropenia in patients receiving chemotherapy for extensive-stage small cell lung cancer (ES-SCLC).
Watch
Case 1: Metastatic NSCLC with an EGFR Exon 20 Insertion
Joel Neal, MD, PhD, presents the case of a 66-year-old woman with no smoking history and a diagnosis of EGFR exon 20 mutation-positive mNSCLC.
Watch
Common Biomarker Testing Methodologies Utilized in NSCLC
Zosia Piotrowska, MD, explains molecular testing methods that can discover molecular alterations in common biomarkers in patients with mNSCLC.
Watch